AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. BPMC
  4. [Form 4] Blueprint Medicines Corporation Insider Trading Activity

[Form 4] Blueprint Medicines Corporation Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Blueprint Medicines Director Habib J. Dable received a grant of 3,902 restricted stock units (RSUs) on June 18, 2025, at a reference price of $128.12 per share. Following this transaction, Dable directly owns 12,644 shares of the company.

Key details of the RSU grant:

  • Vesting occurs 100% on the earlier of June 18, 2026, or the next annual stockholder meeting
  • Each RSU represents the right to receive one share of common stock upon vesting
  • The transaction was reported via Form 4 filing, indicating changes in beneficial ownership

This equity grant appears to be part of the company's director compensation program, aligning the director's interests with those of shareholders through stock ownership. The filing was signed by Melissa Masse as attorney-in-fact on June 23, 2025.

Habib J. Dable, Direttore di Blueprint Medicines, ha ricevuto il 18 giugno 2025 una concessione di 3.902 unit脿 azionarie vincolate (RSU) al prezzo di riferimento di 128,12 $ per azione. Dopo questa operazione, Dable detiene direttamente 12.644 azioni della societ脿.

Dettagli principali della concessione di RSU:

  • Il vesting avviene al 100% alla data anticipata tra il 18 giugno 2026 o la successiva assemblea annuale degli azionisti
  • Ogni RSU d脿 diritto a ricevere una azione ordinaria al momento del vesting
  • L鈥檕perazione 猫 stata comunicata tramite la presentazione del Modulo 4, che indica variazioni nella propriet脿 effettiva

Questa assegnazione di azioni fa parte del programma di compensazione dei direttori della societ脿, allineando gli interessi del direttore con quelli degli azionisti attraverso la propriet脿 azionaria. La presentazione 猫 stata firmata da Melissa Masse in qualit脿 di procuratore il 23 giugno 2025.

Habib J. Dable, Director de Blueprint Medicines, recibi贸 una concesi贸n de 3,902 unidades restringidas de acciones (RSU) el 18 de junio de 2025, a un precio de referencia de $128.12 por acci贸n. Tras esta transacci贸n, Dable posee directamente 12,644 acciones de la compa帽铆a.

Detalles clave de la concesi贸n de RSU:

  • La adquisici贸n total se realiza en la fecha que ocurra primero entre el 18 de junio de 2026 o la pr贸xima junta anual de accionistas
  • Cada RSU representa el derecho a recibir una acci贸n com煤n al momento de la adquisici贸n
  • La transacci贸n fue reportada mediante la presentaci贸n del Formulario 4, que indica cambios en la propiedad beneficiaria

Esta concesi贸n de acciones parece formar parte del programa de compensaci贸n para directores de la empresa, alineando los intereses del director con los de los accionistas a trav茅s de la propiedad accionaria. La presentaci贸n fue firmada por Melissa Masse como apoderada el 23 de junio de 2025.

Blueprint Medicines鞚� 鞚挫偓 Habib J. Dable電� 2025雲� 6鞗� 18鞚� 欤茧嫻 $128.12鞚� 旮办 臧�瓴╈溂搿� 3,902臧滌潣 鞝滍暅 欤检嫕 雼渼(RSU)毳� 攵�鞐皼鞎橃姷雼堧嫟. 鞚� 瓯半灅 鞚错泟, Dable鞚� 須岇偓 欤检嫕 12,644欤茧ゼ 歆侅爲 氤挫湢頃橁矊 霅橃棃鞀惦媹雼�.

RSU 攵�鞐潣 欤检殧 雮挫毄:

  • 氩犾姢韺呾潃 2026雲� 6鞗� 18鞚� 霕愲姅 雼れ潓 鞐半 欤检＜齑濏殞 欷� 牍犽ジ 鞁滌爯鞐� 100% 鞕勲霅╇媹雼�
  • 臧� RSU電� 氩犾姢韺� 鞁� 氤错喌欤� 1欤茧ゼ 氚涭潉 甓岆Μ毳� 雮橅儉雰呺媹雼�
  • 鞚� 瓯半灅電� 靻岇湢甓� 氤�霃欖潉 鞎岆Μ電� Form 4 鞝滌稖鞚� 韱淀暣 氤搓碃霅橃棃鞀惦媹雼�

鞚措矆 欤检嫕 攵�鞐姅 鞚挫偓鞚� 氤挫儊 頂勲攴鸽灗鞚� 鞚柬櫂鞙茧, 欤检嫕 靻岇湢毳� 韱淀暣 鞚挫偓鞕� 欤检＜ 臧� 鞚错暣甏�瓿勲ゼ 鞚检箻鞁滍偆旮� 鞙勴暅 瓴冹瀰雼堧嫟. 鞝滌稖 靹滊電� 2025雲� 6鞗� 23鞚� Melissa Masse臧� 雽�毽澑 鞛愱博鞙茧 靹滊獏頃橃榾鞀惦媹雼�.

Habib J. Dable, administrateur de Blueprint Medicines, a re莽u le 18 juin 2025 une attribution de 3 902 unit茅s d'actions restreintes (RSU) au prix de r茅f茅rence de 128,12 $ par action. Suite 脿 cette op茅ration, Dable d茅tient directement 12 644 actions de la soci茅t茅.

D茅tails cl茅s de l'attribution des RSU :

  • L'acquisition se r茅alise 脿 100 % 脿 la date la plus proche entre le 18 juin 2026 ou la prochaine assembl茅e annuelle des actionnaires
  • Chaque RSU donne droit 脿 une action ordinaire lors de l'acquisition
  • La transaction a 茅t茅 d茅clar茅e via le d茅p么t du formulaire 4, indiquant des changements dans la propri茅t茅 b茅n茅ficiaire

Cette attribution d'actions semble faire partie du programme de r茅mun茅ration des administrateurs de la soci茅t茅, alignant les int茅r锚ts de l'administrateur avec ceux des actionnaires par la d茅tention d'actions. Le d茅p么t a 茅t茅 sign茅 par Melissa Masse en tant que mandataire le 23 juin 2025.

Habib J. Dable, Direktor von Blueprint Medicines, erhielt am 18. Juni 2025 eine Zuteilung von 3.902 eingeschr盲nkten Aktieneinheiten (RSUs) zu einem Referenzpreis von 128,12 $ pro Aktie. Nach dieser Transaktion besitzt Dable direkt 12.644 Aktien des Unternehmens.

Wichtige Details zur RSU-Zuteilung:

  • Die Vesting erfolgt zu 100 % am fr眉heren Zeitpunkt zwischen dem 18. Juni 2026 oder der n盲chsten j盲hrlichen Hauptversammlung
  • Jede RSU berechtigt zum Erhalt einer Stammaktie bei Vesting
  • Die Transaktion wurde 眉ber die Einreichung des Formulars 4 gemeldet, das 脛nderungen im wirtschaftlichen Eigentum anzeigt

Diese Aktienzuteilung scheint Teil des Verg眉tungsprogramms f眉r Direktoren des Unternehmens zu sein, um die Interessen des Direktors durch Aktienbesitz mit denen der Aktion盲re in Einklang zu bringen. Die Einreichung wurde am 23. Juni 2025 von Melissa Masse als Bevollm盲chtigte unterzeichnet.

Positive
  • None.
Negative
  • None.

Habib J. Dable, Direttore di Blueprint Medicines, ha ricevuto il 18 giugno 2025 una concessione di 3.902 unit脿 azionarie vincolate (RSU) al prezzo di riferimento di 128,12 $ per azione. Dopo questa operazione, Dable detiene direttamente 12.644 azioni della societ脿.

Dettagli principali della concessione di RSU:

  • Il vesting avviene al 100% alla data anticipata tra il 18 giugno 2026 o la successiva assemblea annuale degli azionisti
  • Ogni RSU d脿 diritto a ricevere una azione ordinaria al momento del vesting
  • L鈥檕perazione 猫 stata comunicata tramite la presentazione del Modulo 4, che indica variazioni nella propriet脿 effettiva

Questa assegnazione di azioni fa parte del programma di compensazione dei direttori della societ脿, allineando gli interessi del direttore con quelli degli azionisti attraverso la propriet脿 azionaria. La presentazione 猫 stata firmata da Melissa Masse in qualit脿 di procuratore il 23 giugno 2025.

Habib J. Dable, Director de Blueprint Medicines, recibi贸 una concesi贸n de 3,902 unidades restringidas de acciones (RSU) el 18 de junio de 2025, a un precio de referencia de $128.12 por acci贸n. Tras esta transacci贸n, Dable posee directamente 12,644 acciones de la compa帽铆a.

Detalles clave de la concesi贸n de RSU:

  • La adquisici贸n total se realiza en la fecha que ocurra primero entre el 18 de junio de 2026 o la pr贸xima junta anual de accionistas
  • Cada RSU representa el derecho a recibir una acci贸n com煤n al momento de la adquisici贸n
  • La transacci贸n fue reportada mediante la presentaci贸n del Formulario 4, que indica cambios en la propiedad beneficiaria

Esta concesi贸n de acciones parece formar parte del programa de compensaci贸n para directores de la empresa, alineando los intereses del director con los de los accionistas a trav茅s de la propiedad accionaria. La presentaci贸n fue firmada por Melissa Masse como apoderada el 23 de junio de 2025.

Blueprint Medicines鞚� 鞚挫偓 Habib J. Dable電� 2025雲� 6鞗� 18鞚� 欤茧嫻 $128.12鞚� 旮办 臧�瓴╈溂搿� 3,902臧滌潣 鞝滍暅 欤检嫕 雼渼(RSU)毳� 攵�鞐皼鞎橃姷雼堧嫟. 鞚� 瓯半灅 鞚错泟, Dable鞚� 須岇偓 欤检嫕 12,644欤茧ゼ 歆侅爲 氤挫湢頃橁矊 霅橃棃鞀惦媹雼�.

RSU 攵�鞐潣 欤检殧 雮挫毄:

  • 氩犾姢韺呾潃 2026雲� 6鞗� 18鞚� 霕愲姅 雼れ潓 鞐半 欤检＜齑濏殞 欷� 牍犽ジ 鞁滌爯鞐� 100% 鞕勲霅╇媹雼�
  • 臧� RSU電� 氩犾姢韺� 鞁� 氤错喌欤� 1欤茧ゼ 氚涭潉 甓岆Μ毳� 雮橅儉雰呺媹雼�
  • 鞚� 瓯半灅電� 靻岇湢甓� 氤�霃欖潉 鞎岆Μ電� Form 4 鞝滌稖鞚� 韱淀暣 氤搓碃霅橃棃鞀惦媹雼�

鞚措矆 欤检嫕 攵�鞐姅 鞚挫偓鞚� 氤挫儊 頂勲攴鸽灗鞚� 鞚柬櫂鞙茧, 欤检嫕 靻岇湢毳� 韱淀暣 鞚挫偓鞕� 欤检＜ 臧� 鞚错暣甏�瓿勲ゼ 鞚检箻鞁滍偆旮� 鞙勴暅 瓴冹瀰雼堧嫟. 鞝滌稖 靹滊電� 2025雲� 6鞗� 23鞚� Melissa Masse臧� 雽�毽澑 鞛愱博鞙茧 靹滊獏頃橃榾鞀惦媹雼�.

Habib J. Dable, administrateur de Blueprint Medicines, a re莽u le 18 juin 2025 une attribution de 3 902 unit茅s d'actions restreintes (RSU) au prix de r茅f茅rence de 128,12 $ par action. Suite 脿 cette op茅ration, Dable d茅tient directement 12 644 actions de la soci茅t茅.

D茅tails cl茅s de l'attribution des RSU :

  • L'acquisition se r茅alise 脿 100 % 脿 la date la plus proche entre le 18 juin 2026 ou la prochaine assembl茅e annuelle des actionnaires
  • Chaque RSU donne droit 脿 une action ordinaire lors de l'acquisition
  • La transaction a 茅t茅 d茅clar茅e via le d茅p么t du formulaire 4, indiquant des changements dans la propri茅t茅 b茅n茅ficiaire

Cette attribution d'actions semble faire partie du programme de r茅mun茅ration des administrateurs de la soci茅t茅, alignant les int茅r锚ts de l'administrateur avec ceux des actionnaires par la d茅tention d'actions. Le d茅p么t a 茅t茅 sign茅 par Melissa Masse en tant que mandataire le 23 juin 2025.

Habib J. Dable, Direktor von Blueprint Medicines, erhielt am 18. Juni 2025 eine Zuteilung von 3.902 eingeschr盲nkten Aktieneinheiten (RSUs) zu einem Referenzpreis von 128,12 $ pro Aktie. Nach dieser Transaktion besitzt Dable direkt 12.644 Aktien des Unternehmens.

Wichtige Details zur RSU-Zuteilung:

  • Die Vesting erfolgt zu 100 % am fr眉heren Zeitpunkt zwischen dem 18. Juni 2026 oder der n盲chsten j盲hrlichen Hauptversammlung
  • Jede RSU berechtigt zum Erhalt einer Stammaktie bei Vesting
  • Die Transaktion wurde 眉ber die Einreichung des Formulars 4 gemeldet, das 脛nderungen im wirtschaftlichen Eigentum anzeigt

Diese Aktienzuteilung scheint Teil des Verg眉tungsprogramms f眉r Direktoren des Unternehmens zu sein, um die Interessen des Direktors durch Aktienbesitz mit denen der Aktion盲re in Einklang zu bringen. Die Einreichung wurde am 23. Juni 2025 von Melissa Masse als Bevollm盲chtigte unterzeichnet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Dable Habib J
(Last) (First) (Middle)
C/O BLUEPRINT MEDICINES CORPORATION
45 S
(Street)
CAMBRIDGE MA 02139
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Blueprint Medicines Corp [ BPMC ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/18/2025 A 3,902(1) A $128.12 12,644 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) June 18, 2026 and (ii) the next annual meeting of the Issuer's stockholders. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
/s/ Melissa Masse, Attorney-in-Fact 06/23/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many BPMC shares did Director Habib J Dable acquire on June 18, 2025?

Director Habib J Dable acquired 3,902 shares of BPMC common stock in the form of restricted stock units (RSUs) on June 18, 2025, at a price of $128.12 per share.

What are the vesting terms for BPMC Director Dable's June 2025 RSU grant?

The restricted stock units vest 100% on the earlier of (i) June 18, 2026 or (ii) the next annual meeting of Blueprint Medicines' stockholders. Each RSU represents a right to receive one share of common stock.

How many total BPMC shares does Habib Dable own after the June 2025 transaction?

Following the reported RSU grant transaction, Habib Dable beneficially owns 12,644 shares of Blueprint Medicines (BPMC) common stock directly.

What position does Habib Dable hold at BPMC according to the Form 4?

According to the Form 4 filing, Habib J Dable serves as a Director of Blueprint Medicines Corporation (BPMC), as indicated by the 'X' marked in the Director box under the Relationship of Reporting Person(s) to Issuer section.
Stock BPMC logo
Blueprint Medicines Corp

NASDAQ:BPMC

BPMC Rankings

#1013 Ranked by Market Cap
N/A Ranked by Dividends

BPMC Latest News

Jun 12, 2025
Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT庐/AYVAKYT庐 (avapritinib) Treatment at 2025 EHA and EAACI Congresses
Jun 2, 2025
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
May 1, 2025
Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT庐/AYVAKYT庐 (avapritinib) Full Year Revenue Guidance
Apr 25, 2025
Blueprint Medicines to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
Mar 31, 2025
Blueprint Medicines to Present at 24th Annual Needham Virtual Healthcare Conference

BPMC Latest SEC Filings

Aug 14, 2025
[SCHEDULE 13G] Blueprint Medicines Corporation SEC Filing
Aug 14, 2025
[SCHEDULE 13G/A] Blueprint Medicines Corporation SEC Filing
Aug 14, 2025
[SCHEDULE 13G/A] Blueprint Medicines Corporation SEC Filing
Jul 28, 2025
[15-12G] Blueprint Medicines Corporation SEC Filing
Jul 21, 2025
[Form 4] Blueprint Medicines Corporation Insider Trading Activity

BPMC Stock Data

8.35B
63.82M
0.88%
109.19%
4.84%
Biotechnology
Pharmaceutical Preparations
United States
CAMBRIDGE